Cargando…
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297299/ https://www.ncbi.nlm.nih.gov/pubmed/26960721 http://dx.doi.org/10.1093/jac/dkw079 |
| _version_ | 1783546974096588800 |
|---|---|
| author | Cornely, Oliver A. Duarte, Rafael F. Haider, Shariq Chandrasekar, Pranatharthi Helfgott, David Jiménez, Javier López Candoni, Anna Raad, Issam Laverdiere, Michel Langston, Amelia Kartsonis, Nicholas Van Iersel, Marlou Connelly, Nancy Waskin, Hetty |
| author_facet | Cornely, Oliver A. Duarte, Rafael F. Haider, Shariq Chandrasekar, Pranatharthi Helfgott, David Jiménez, Javier López Candoni, Anna Raad, Issam Laverdiere, Michel Langston, Amelia Kartsonis, Nicholas Van Iersel, Marlou Connelly, Nancy Waskin, Hetty |
| author_sort | Cornely, Oliver A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7297299 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72972992020-06-22 Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease Cornely, Oliver A. Duarte, Rafael F. Haider, Shariq Chandrasekar, Pranatharthi Helfgott, David Jiménez, Javier López Candoni, Anna Raad, Issam Laverdiere, Michel Langston, Amelia Kartsonis, Nicholas Van Iersel, Marlou Connelly, Nancy Waskin, Hetty J Antimicrob Chemother Errata Oxford University Press 2016-06 2016-03-08 /pmc/articles/PMC7297299/ /pubmed/26960721 http://dx.doi.org/10.1093/jac/dkw079 Text en © The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Errata Cornely, Oliver A. Duarte, Rafael F. Haider, Shariq Chandrasekar, Pranatharthi Helfgott, David Jiménez, Javier López Candoni, Anna Raad, Issam Laverdiere, Michel Langston, Amelia Kartsonis, Nicholas Van Iersel, Marlou Connelly, Nancy Waskin, Hetty Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease |
| title | Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease |
| title_full | Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease |
| title_fullStr | Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease |
| title_full_unstemmed | Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease |
| title_short | Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease |
| title_sort | phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease |
| topic | Errata |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297299/ https://www.ncbi.nlm.nih.gov/pubmed/26960721 http://dx.doi.org/10.1093/jac/dkw079 |
| work_keys_str_mv | AT cornelyolivera phase3pharmacokineticsandsafetystudyofaposaconazoletabletformulationinpatientsatriskforinvasivefungaldisease AT duarterafaelf phase3pharmacokineticsandsafetystudyofaposaconazoletabletformulationinpatientsatriskforinvasivefungaldisease AT haidershariq phase3pharmacokineticsandsafetystudyofaposaconazoletabletformulationinpatientsatriskforinvasivefungaldisease AT chandrasekarpranatharthi phase3pharmacokineticsandsafetystudyofaposaconazoletabletformulationinpatientsatriskforinvasivefungaldisease AT helfgottdavid phase3pharmacokineticsandsafetystudyofaposaconazoletabletformulationinpatientsatriskforinvasivefungaldisease AT jimenezjavierlopez phase3pharmacokineticsandsafetystudyofaposaconazoletabletformulationinpatientsatriskforinvasivefungaldisease AT candonianna phase3pharmacokineticsandsafetystudyofaposaconazoletabletformulationinpatientsatriskforinvasivefungaldisease AT raadissam phase3pharmacokineticsandsafetystudyofaposaconazoletabletformulationinpatientsatriskforinvasivefungaldisease AT laverdieremichel phase3pharmacokineticsandsafetystudyofaposaconazoletabletformulationinpatientsatriskforinvasivefungaldisease AT langstonamelia phase3pharmacokineticsandsafetystudyofaposaconazoletabletformulationinpatientsatriskforinvasivefungaldisease AT kartsonisnicholas phase3pharmacokineticsandsafetystudyofaposaconazoletabletformulationinpatientsatriskforinvasivefungaldisease AT vanierselmarlou phase3pharmacokineticsandsafetystudyofaposaconazoletabletformulationinpatientsatriskforinvasivefungaldisease AT connellynancy phase3pharmacokineticsandsafetystudyofaposaconazoletabletformulationinpatientsatriskforinvasivefungaldisease AT waskinhetty phase3pharmacokineticsandsafetystudyofaposaconazoletabletformulationinpatientsatriskforinvasivefungaldisease |